Longeveron (LGVN) FCF Margin Growth (1y) (2021 - 2026)
Longeveron (LGVN) FCF Margin Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -89.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1,183.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 26,102.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 869.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 769.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 4,109.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 19,111.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.00 |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -81,633.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -81,633.00 |
| Mar 31, 2026 | 14,191.00 |
| Dec 31, 2025 | -88,943.00 |
| Sep 30, 2025 | -330,797.00 |
| Jun 30, 2025 | -17,172.00 |
| Mar 31, 2025 | -67,384.00 |
| Dec 31, 2024 | 604,324.00 |
| Sep 30, 2024 | 261,592.00 |
| Jun 30, 2024 | 114,515.00 |
| Mar 31, 2024 | 154,505.00 |
| Dec 31, 2023 | -464,278.00 |
| Sep 30, 2023 | 157,267.00 |
| Jun 30, 2023 | -144,314.00 |
| Mar 31, 2023 | -75,659.00 |
| Dec 31, 2022 | -119,978.00 |
| Sep 30, 2022 | -359,002.00 |
| Jun 30, 2022 | -11,585.00 |
| Mar 31, 2022 | -54,813.00 |
| Sep 30, 2021 | -100,879.00 |
| Jun 30, 2021 | -19,401.00 |